Boundless Bio's BBI-940 IND Accepted by FDA, Clinical Trial to Start in 2026
Boundless Bio announced that the U.S. Food and Drug Administration, FDA, has accepted its Investigational New Drug, IND, application for its novel Kinesin oral degrader program, BBI-940. The acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer, KOMODO-1, which is expected to initiate in the first half of 2026. The Company expects to deliver initial proof-of-concept clinical data within its cash runway timeline. Based on the revised operating plan, the Company's streamlined operations will extend its operating runway into the second half of 2028, through the anticipated initial clinical proof of concept readout for BBI-940.
Trade with 70% Backtested Accuracy
Analyst Views on BOLD
About BOLD
About the author
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.